The Canadian Biomarker Integration Network in Depression

What The Canadian Biomarker Integration Network in Depression does

The Canadian Biomarker Integration Network in Depression (CAN-BIND) is a national, non-profit academic research network established in 2011 under sponsorship of the Ontario Brain Institute and headquartered in Toronto, Canada. Its mission is to discover biomarker-based methods that identify the right depression treatment for the right patient, shortening the path to recovery through precision medicine. The organization operates six integrated research platforms — Clinical, Neuroimaging (fMRI, structural MRI, DTI), Molecular (DNA, RNA, proteins, blood/urine), Electroencephalography (EEG), Data Science (machine learning and deep learning), and Digital Health (behavioral sensing, ecological momentary assessment) — supported by a Knowledge Translation & Outreach Platform that moves findings into clinical guidelines and public education.

CAN-BIND's research is delivered through four actively recruiting clinical studies (OPTIMUM-D, PERFORM-D, ENABLE, LIMIT-D) conducted across 12+ research sites and 23 partner universities and health centres in Canada, with additional collaborators at the University of Michigan and UT Southwestern. As of the available data, the network has enrolled 1,500+ research participants, produced 170+ peer-reviewed publications, and developed 600+ educational and resource materials, including contributions to the CANMAT Depression Treatment Guidelines. The organization has trained close to 100 trainees since 2011 and continues to expand into new modalities such as a Psychedelics Platform.

CAN-BIND does not sell products or services and has no disclosed pricing model. Its financial model is grant-based: core funding comes from the Ontario Brain Institute, supplemented by partners such as Bell Let's Talk. Its go-to-market is fundamentally research-network driven — recruiting participants through clinical studies at academic sites, disseminating findings via publications, webinars, podcasts, and educational resources, and convening community and clinician engagement through annual workshops and its Community Advisory Committee. Customer segments are individuals living with depression (research participants), healthcare providers, and clinical researchers, with no commercial transaction in the chain.

Name

The Canadian Biomarker Integration Network in Depression

Legal name

The Canadian Biomarker Integration Network in Depression

Website

https://canbind.ca

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

CAN-BIND is a Canadian non-profit research network, founded in 2011 and sponsored by the Ontario Brain Institute, that uses six integrated platforms to discover biomarkers predicting depression treatment response across 23 partner universities and health centres.

Ownership category

akta.pro rank

Product category

Mental Health Research Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industry

Behavioral Health & Substance Use Remote Monitoring (HLACAFAD)

Keywords

• Depression biomarker research
• Clinical research network
• Precision mental health
• Translational neuroscience
• Multi-site clinical trials

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices15 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Ontario Brain Institute Funding: CAN-BIND is sponsored by the Ontario Brain Institute (OBI) as one of multiple integrated discovery programs focused on depression. OBI provides core funding for the network's operations and research activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

The Canadian Biomarker Integration Network in Depression (CAN-BIND) is a national research program that runs multi-site clinical biomarker studies to identify the right treatment for the right person with depression. Its deliverables include four active clinical studies (OPTIMUM-D, PERFORM-D, ENABLE, LIMIT-D), seven integrated research platforms (Clinical, Neuroimaging, Molecular, EEG, Data Science, Digital Health, Knowledge Translation), evidence-based clinical guidelines, and free public education resources such as the CHOICE-D Guide to Depression Treatment.

Product overview

CAN-BIND (Canadian Biomarker Integration Network in Depression) is a national research program and learning network focused on discovering ways to identify the right treatment for the right person with depression. The organization operates as a multi-platform research infrastructure consisting of six integrated research platforms (Clinical, Neuroimaging, Molecular, EEG, Data Science, and Digital Health) supported by a Knowledge Translation & Outreach Platform. The core research is conducted through four active clinical studies: OPTIMUM-D, PERFORM-D, ENABLE, and LIMIT-D. Educational offerings include the CHOICE-D Guide to Depression Treatment, CANMAT Depression Treatment Guidelines, webinars, videos, podcasts, and conference events. The network spans 23 universities and health centres across Canada, collaborating with academic, community, and industry partners to advance precision medicine approaches to depression care.

Differentiator

Problem solved

Functional benefit

Products and services

• OPTIMUM-D Study A recruiting clinical research study investigating biomarkers and treatment outcomes for depression as part of CAN-BIND's precision-medicine research program.
• PERFORM-D Study A recruiting clinical research study investigating depression treatment responses and biomarkers within CAN-BIND's biomarker discovery program.
• ENABLE Platform A recruiting research platform focused on enabling precision-medicine approaches for depression treatment, led by the ENABLE Platform team at McMaster University & St. Joseph's Healthcare Hamilton.
• LIMIT-D Study A recruiting clinical research study examining depression biomarkers and treatment responses, led by Raymond Lam at the University of British Columbia.
• Digital Health Platform A CAN-BIND research platform focused on measurement-based care, wellness promotion, ongoing monitoring, and relapse prevention using behavioural sensing, ecological momentary assessment (EMA), and digital engagement tools.
• Clinical Platform A CAN-BIND research platform responsible for development of study protocols, defining study populations, selecting study designs, ensuring safety standards, and determining clinical assessments across study sites.
• Neuroimaging Platform A CAN-BIND research platform that standardizes neuroimaging protocols across study sites, performs quality assurance and quality control, and conducts preliminary analysis of brain imaging data including task-based fMRI, resting-state fMRI, structural MRI, and DTI.
• Molecular Platform A CAN-BIND research platform that examines biological samples including blood and urine to study molecular factors such as DNA, RNA, proteins, and other biological markers related to depression and treatment response.
• Electroencephalography (EEG) Platform A CAN-BIND research platform responsible for collection, standardization, and analysis of brain electrical activity data to identify EEG-based biomarkers for depression diagnosis and treatment response prediction, including measurements at rest, during functional tasks, and in response to transcranial magnetic stimulation.
• Data Science Platform A CAN-BIND research platform that uses machine learning, deep learning, and biostatistics to analyze multi-source datasets and develop models for treatment response prediction and depression subtype identification.
• Knowledge Translation & Outreach Platform A CAN-BIND research platform dedicated to moving research findings into clinical practice and health policy through seminars, workshops, webinars, educational videos, and social media engagement.
• CHOICE-D Guide to Depression Treatment A free public education resource that increases mental health literacy and depression awareness through events, workshops, and downloadable educational materials.
• CANMAT Depression Treatment Guidelines for Clinicians Evidence-based clinical guidelines produced by the Canadian Network for Mood and Anxiety Treatments (CANMAT) for the management of depression in adults, with updates released in 2009, 2016, and 2023.
• Webinars for Healthcare Providers Educational webinar series for healthcare providers covering topics such as anhedonia measurement, sleep and circadian rhythms, exercise for depression, and gut-brain connections for mental health.
• Videos for Healthcare Providers Video library featuring CBT tips, CANMAT guidelines overview, suicide prevention, rTMS information, and cognitive deficit research for healthcare professionals.
• CAN-BIND Podcasts Podcast series exploring topics including neuroplasticity, psychedelics, ketamine vs ECT, AI in mental health, and mental health policy in Canada, distributed via SoundCloud and the CAN-BIND website.
• Psychedelics in Canada Conference Conference on psychedelics in Canada featuring clinic-inspired and evidence-based discussions on psychedelic medicine, neuroplasticity, and therapeutic applications.
• Patient and Family Guide to Bipolar Disorder Management Free downloadable guide for patients and families based on CANMAT and ISBD guidelines for management of bipolar disorder.
• Resources and Support for Depression Compilation of mental health resources including crisis helplines (988, Kids Help Phone, Hope for Wellness), support services, and educational materials for individuals affected by depression.

Quantifiable outcome

• 170+ peer-reviewed publications produced since program inception
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• 23 Universities and Health CentrescoreStrategic or Co-development PartnerCollaborating institutions including McMaster University, University of British Columbia, Dalhousie University, McGill University, University of Calgary, Queen's University, Simon Fraser University, and multiple hospital research sites. Provides research infrastructure, personnel, and expertise.
• Community OrganizationscoreStrategic or Co-development PartnerAcademic and community organizations partner to extend research opportunities and enhance support for individuals and families living with mood disorders. Includes advocacy groups and lived experience organizations.
• University of Texas Southwestern Medical CentercoreStrategic or Co-development PartnerCollaborating research institution for the Molecular Platform, extending the platform's capabilities in biomarker research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• National Institute of Mental Health (NIMH): Largest US funder of mental health research; comparable in driving large-scale depression biomarker and treatment-response initiatives, with overlapping investigator networks.
• Ontario Brain Institute: Provincial research funder and parent organization that sponsors CAN-BIND along with multiple other integrated discovery programs across neurological and psychiatric conditions.
• Centre for Addiction and Mental Health (CAMH): Canada's largest mental health teaching hospital and a key CAN-BIND site lead institution (Digital Health Platform, CAMH Site Co-Lead) — comparable scope of depression and biomarker research activity.

Regional players

• Black Dog Institute: Australian clinical and research institute focused on mood disorders including depression, with comparable translational research linking biomarkers, digital tools, and clinical practice in mental health.

Direct peers

• NEWMEDS (Novel Methods leading to New Medications in Depression and Schizophrenia): European multi-site research consortium focused on biomarker discovery and treatment response prediction in depression and schizophrenia, comparable in network-driven multi-platform approach.
• EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care): US-based NIMH-funded depression biomarker discovery consortium integrating clinical, neuroimaging, and molecular measures — the closest international analog to CAN-BIND's mission, design, and methods.
• iSPOT-D (International Study to Predict Optimized Treatment in Depression): International multi-site precision-medicine trial that, like CAN-BIND, sought to predict antidepressant treatment response using biological and clinical markers — directly comparable mission and study design.

Emerging players

• Brain Health Registry (UCSF): Large-scale online registry collecting cognitive, behavioral, and biomarker data at scale to accelerate brain-disorder research — comparable in using digital tools to grow research participant datasets.
• Sage Bionetworks: Non-profit biomedical research organization applying open-data and computational approaches to disease consortia, including mental health — comparable in building shared data infrastructure for collaborative research.

Others

• One Mind / Brain & Behavior Research Foundation: Non-profit research funder and accelerator focused on brain and mental health research — comparable as a catalyst for translational mental health research consortia, though operating as funder rather than investigator network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CANBIND
• YouTubeyoutube.com/channel/UCg4kcBvDoJtDOBDO7UxEwkQ
• Facebookfacebook.com/CANBIND
• LinkedInlinkedin.com/company/can-bind

Revenue estimate

Valuation estimate

Number of profiles

Profiles33 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Canadian Biomarker Integration Network in Depression